Potential Drug Target or Biomarker AHI1-DT (G100131814)

Target Name: AHI1-DT

NCBI ID: G100131814

AHI1-DT

Potential Drug Target or Biomarker AHI1-DT

The AHI1-DT (AHI1 divergent transcript) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The AHI1 gene is located on chromosome 18q and encodes for a protein known as AHI1, which is involved in a variety of cellular processes including cell adhesion, migration, and survival. The AHI1-DT has been shown to play a crucial role in the regulation of these processes and is a promising target for therapeutic intervention.

Drug Target Potential

The AHI1-DT has been identified as a potential drug target due to its unique structure and function. The AHI1-DT is a non-coding RNA molecule that can interact with the protein AHI1, which is a seven-transmembrane protein involved in cell adhesion and migration. This interaction between the AHI1-DT and AHI1 suggests that the AHI1-DT may be a useful target for small molecule inhibitors that can modulate the activity of AHI1.

In addition to its potential as a drug target, the AHI1-DT has also been identified as a potential biomarker for a variety of diseases. The AHI1 gene is known to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The AHI1-DT has been shown to be expressed in a variety of tissues and conditions, including cancer cells, neurotransmitter-induced synaptic plasticity, and autoimmune mouse models.

Expression and Localization

The AHI1 gene is located on chromosome 18q and has been shown to encode for a protein that is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. The AHI1 protein is a seven-transmembrane protein that is involved in the regulation of adhesion molecule interactions, cytoskeletal organization, and survival signaling pathways. The AHI1-DT has been shown to be a stable RNA molecule that is expressed in various tissues and conditions, including cancer cells, neurotransmitter-induced synaptic plasticity, and autoimmune mouse models.

The localization of the AHI1-DT has been determined through a variety of techniques, including RNA sequencing, RNA immunoprecipitation, and in vitro transcription assays. These studies have shown that the AHI1-DT is expressed in various tissues and conditions, including cancer cells, neurotransmitter-induced synaptic plasticity, and autoimmune mouse models. The AHI1-DT has been shown to be expressed in the nuclei of these cells and to interact with the protein AHI1.

Function and Interaction

The AHI1-DT has been shown to play a crucial role in the regulation of various cellular processes, including cell adhesion, migration, and survival. One of the most significant functions of the AHI1-DT is its role in the regulation of cell adhesion. The AHI1-DT has been shown to be involved in the regulation of adhesion molecule interactions and to play a role in the formation of tight junctions, which are a type of cell-cell adhesion structure.

In addition to its role in cell adhesion, the AHI1-DT has also been shown to play a role in the regulation of cell migration. The AHI1-DT has been shown to be involved in the regulation of the migration of various cell types, including cancer cells, and to play a role in the regulation of cell migration in neurotransmitter-induced synaptic plasticity.

The AHI1-DT has also been shown to play a role in the regulation of

Protein Name: AHI1 Divergent Transcript

The "AHI1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AHI1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets